Indiana § 12-15-35.5-7 Limitations on drug refills

Indiana Statutes

§ 12-15-35.5-7 — Limitations on drug refills

Indiana § 12-15-35.5-7

Art. 15MEDICAID

Ch. 35.5Prescription Drugs

This text of Indiana § 12-15-35.5-7 (Limitations on drug refills) is published on Counsel Stack Legal Research, covering Indiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ind. Code § 12-15-35.5-7 (2026).

Text

(a)Subject to subsection (b), the office may place limits on quantities dispensed or the frequency of refills for any covered drug as required by law or for the purpose of:

(1)preventing fraud, abuse, or waste;

(2)preventing overutilization, inappropriate utilization, or inappropriate prescription practices that are contrary to:

(A)clinical quality and patient safety; and

(B)accepted clinical practice for the diagnosis and treatment of mental illness and the considerations specified in subsection

(h); or

(3)implementing a disease management program.

(b)Before implementing a limit described in subsection (a), the office shall:

(1)consider quality of care and the best interests of Medicaid recipients;

(2)seek the advice of the drug utilization review board, established by IC 12-15-3

Free access — add to your briefcase to read the full text and ask questions with AI

(a) Subject to subsection (b), the office may
place limits on quantities dispensed or the frequency of refills for any
covered drug as required by law or for the purpose of:
(1) preventing fraud, abuse, or waste;
(2) preventing overutilization, inappropriate utilization, or
inappropriate prescription practices that are contrary to:
(A) clinical quality and patient safety; and
(B) accepted clinical practice for the diagnosis and treatment of
mental illness and the considerations specified in subsection
(h); or
(3) implementing a disease management program.
(b) Before implementing a limit described in subsection (a), the
office shall:
(1) consider quality of care and the best interests of Medicaid
recipients;
(2) seek the advice of the drug utilization review board,
established by IC 12-15-35-19, at a public meeting of the board;
and
(3) publish a provider bulletin that complies with the
requirements of IC 12-15-13-6.

Legislative History

As added by P.L.6-2002, SEC.4. Amended by P.L.184-2003, SEC.11; P.L.101-2005, SEC.7; P.L.8-2007, SEC.1; P.L.36-2009, SEC.3; P.L.229-2011, SEC.145; P.L.7-2015, SEC.35; P.L.210-2015, SEC.51; P.L.213-2025, SEC.118.